CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
LND101 for Fecal Microbiota Transplantation in Combination with Immune Checkpoint Blockade in Patients with Advanced Melanoma
Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (TRIPLE-SWITCH)
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Advanced, Colorectal Adenocarcinoma: The BATTMAN Trial
Delayed Reduced Volume and Dose Elective Ratiotherapy (REVERT) in Patients with HNSCC
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
CCTG is pleased to announce that the OV.25 trial, A Randomized Phase II Double-Blind Placebo-Controlled Trial of Acetylsalicylic Acid (ASA) in Prevention of Ovarian Cancer in Women with BRCA 1/2 Mutations (STICs and STONEs) has been centrally activated.
Reminder: Feedback request on Health Canada Guidance GUI-0100 due April 2, 2018
The Central Operations and Statistics Office located at Queen's University in Kingston, Ontario has current job openings for two Study Coordinators and a Monitor/Auditor. Please visit our career page to find out more about these roles and how to apply.
Congratulations to our colleague Dr. Frances Shepherd, medical oncologist at Princess Margaret Cancer Centre, who has received the prestigious 2018 Canada Gairdner Wightman Award "for her global leadership in oncology which has contributed significantly to the improving survival outcome of lung cancer patients worldwide." Dr. Shepherd served as Chair of the Lung Cancer Committee at CCTG for 19 years!
The MAC.23 trial a Phase III Randomized Trial of Hypofractionated Post-Mastectomy Radiation with Breast Reconstruction has been centrally activated
On-line Registration is now open. Travel and hotel information, a draft Schedule of Events, and our meetings policies, including the Invitation Policy, Registration Policy, and Travel Reimbursement Policy, are posted on the Spring Meeting 2018 Registration and Information page.